Die nicht epithelialen Malignome des Ovars

• Literatur

• 1 Vlasak I, Plöchl E, Kronberger G et al. Screening of patients with Turner syndrome for “hidden” Y-mosaicism. Klin Padiatr 1999; 211: 30-34
• 2 Bianco B, Lipay MV, Melaragno MI et al. Detection of hidden Y mosaicism in Turner’s syndrome: importance in the prevention of gonadoblastoma. J Pediatr Endocrinol Metab 2006; 19: 1113-1117
• 3 McHale MT, DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer. Compr Ther 1999; 25: 144-150
• 4 Kumar S, Shah JP, Bryant CS et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. Gynecol Oncol 2008; 110: 125-132
• 5 Hanigan MH, Frierson HF Jr, Abeler VM et al. Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin. Br J Cancer 1999; 81: 75-79
• 6 Bridgewater JA, Rustin GJ. Management of non-epithelial ovarian tumours. Oncology 1999; 57: 89-98
• 7 de Wit R, Louwerens M, de Mulder PH et al. Management of intermediate-prognosis germ-cell cancer: results of a phase I / II study of Taxol-BEP. Int J Cancer 1999; 83: 831-833
• 8 Kawai M, Kano T, Furuhashi Y et al. Prognostic factors in yolk sac tumors of the ovary. A clinicopathologic analysis of 29 cases. Cancer 1991; 67: 184-192
• 9 Nawa A, Obata N, Kikkawa F et al. Prognostic factors of patients with yolk sac tumors of the ovary. Am J Obstet Gynecol 2001; 184: 1182-1188
• 10 Murugaesu N, Schmid P, Dancey G et al. Malignant ovarian germ cell tumors: identification of novel prognostic markers and long-term outcome after multimodality treatment. J Clin Oncol 2006; 24: 4862-4866
• 11 Mitchell PL, Al-Nasiri N, A’Hern R et al. Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases. Cancer 1999; 85: 2232-2244
• 12 Lai CH, Chang TC, Hsueh S et al. Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol 2005; 96: 784-791
• 13 Williams SD, Blessing JA, Liao SY et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide and bleomycin: a trial of the Gynecologic Oncology Group. J Clin Oncol 1994; 12: 701-706
• 14 Solh HM, Azoury RS, Najjar SS. Peutz-Jeghers syndrome associated with precocious puberty. J Pediatr 1983; 103: 593-595
• 15 Tamimi HK, Bolen JW. Enchondromatosis (Ollier’s disease) and ovarian juvenile granulosa cell tumor. Cancer 1984; 53: 1605-1608
• 16 Tanaka Y, Sasaki Y, Nishihira H et al. Ovarian juvenile granulosa cell tumor associated with Maffucci’s syndrome. Am J Clin Pathol 1992; 97: 523-527
• 17 Van Holsbeke C, Domali E, Holland TK et al. Imaging of gynecological disease (3): clinical and ultrasound characteristics of granulosa cell tumors of the ovary. Ultrasound Obstet Gynecol 2008; 31: 450-456
• 18 Demidov VN, Lipatenkova J, Vikhareva O et al. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. Ultrasound Obstet Gynecol 2008; 31: 85-91
• 19 Vihko KK, Bläuer M, Puistola U et al. Activin B in patients with granulosa cell tumors: serum levels in comparison to inhibin. Acta Obstet Gynecol Scand 2003; 82: 570-574
• 20 Pectasides D, Pectasides E, Psyrri A. Granulosa cell tumor of the ovary. Cancer Treat Rev 2008; 34: 1-12
• 21 Homesley HD, Bundy BN, Hurteau JA et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study. Gynecol Oncol 1999; 72: 131-137
• 22 Brown J, Shvartsman HS, Deavers MT et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 2005; 97: 489-496
• 23 Kauppila A, Bangah M, Burger H et al. GnRH agonist analog therapy in advanced / recurrent granulosa cell tumors: further evidence of a role of inhibin in monitoring response to treatment. Gynecol Endocrinol 1992; 6: 271-274
• 24 Freeman SA, Modesitt SC. Anastrozole therapy in recurrent ovarian adult granulosa cell tumors: a report of 2 cases. Gynecol Oncol 2006; 103: 755-758
• 25 Mom CH, Engelen MJ, Willemse PH et al. Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol 2007; 105: 365-372
• 26 Lane AH, Lee MM, Fuller Jr AF et al. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. Gynecol Oncol 1999; 73: 51-55
• 27 McCluggage WG, McKenna M, McBride HA. CD 56 is a sensitive and diagnostically useful immunhistochemical marker of ovarian sex cord-stromal tumors. Int J Pathol 2007; 26: 322-327
• 28 Widschwendter M, Meduri G, Loosfelt H et al. Fulminant recurrence of a Sertoli-Leydig cell tumour during pregnancy. Br J Obstet Gynaecol 1999; 106: 284-285